Early Access — free while we kick the tires
EdgarHawk

Williams Lewis T

Director

Director
1 filing analyzed · 1 company · Latest 2026-02-18

Companies

Company Buys Sells Direction
Protagonist Therapeutics, Inc PTGX 0 2 Net selling

Activity

February 2026
high
Sell
18,000 shares
$1,483,560
Significance 7/10

Director Williams Lewis T sold 18,000 shares of PTGX at $82.42; holdings reduced 69.7% to 7,825 shares

Director Williams Lewis T executed a material reduction in his PTGX position, selling 18,000 shares (69.7% of his pre-transaction holdings) at $82.42 on 2026-02-17 for a total value of $1,483,560.00. The company is currently unprofitable with a net income of $-39,339,000.00 against quarterly revenue of $4,712,000.00, though it has achieved explosive 624.1% annual revenue growth. At a market cap of $5,188,175,121.34 and P/E of 113.68, the stock is priced at a substantial premium to traditional valuation metrics, and is currently 13.0% below its 52-week high of $95.35. The director's substantial stake reduction leaves only 7,825 shares post-transaction, warranting attention to whether this reflects a structural reassessment of the company's value proposition or capital allocation priorities.

Related insiders

Create a free account

Build watchlists, get email alerts on the tickers you follow, and read the full AI analysis on every insider filing.

Sign up — free during early access